NASDAQ: QLGN
Qualigen Therapeutics Inc Stock Ownership - Who owns Qualigen Therapeutics?

Insider buying vs selling

Have Qualigen Therapeutics Inc insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when QLGN insiders and whales buy or sell their stock.

QLGN Shareholders

What type of owners hold Qualigen Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Noah Doyle1,057.41%7,787,131$27.10MInsider
Javelin Venture Partners LP957.02%7,047,804$24.53MInsider
Sekisui Diagnostics LLC268.90%1,980,233$6.89MInsider
Stonehenge Partners LLC110.98%817,272$2.84MInsider
Javelin Venture Partners I Spv I LLC43.83%322,753$1.12MInsider
Michael S. Poirier28.54%210,207$731.52kInsider
Matthew W. Foehr18.83%138,635$482.45kInsider
Andrew J. Ritter11.18%82,352$286.58kInsider
Ira E. Ritter11.18%82,352$286.58kInsider
Michael D. Step10.46%77,000$267.96kInsider

1 of 3

QLGN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
QLGN0.06%99.94%
ADTX1.52%98.48%Net Selling
REVB1.12%98.88%Net BuyingNet Buying
VIVS12.44%87.56%
KZIA0.48%33.42%

Qualigen Therapeutics Stock Ownership FAQ

Who owns Qualigen Therapeutics?

Qualigen Therapeutics (NASDAQ: QLGN) is owned by 1.47% institutional shareholders, 2,536.81% Qualigen Therapeutics insiders, and 0.00% retail investors. Noah Doyle is the largest individual Qualigen Therapeutics shareholder, owning 7.79M shares representing 1,057.41% of the company. Noah Doyle's Qualigen Therapeutics shares are currently valued at $27.88M.

If you're new to stock investing, here's how to buy Qualigen Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.